Anesthesia Quality Improvement and Patients With Planned ICU Admission
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Nov 22, 2022
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Intensive care unit (ICU) is an important part of perioperative management for high-risk patients but is associated with higher medical costs. Improper ICU admission may produce overtreatment without beneficial effects. Studies found that immediate ICU admission after surgery did not reduce the perioperative mortality. Some authors suggested that the indication of ICU admission should be the occurrence of postoperative complications, which will reasonably reduce the use of medical resources.
In clinical practice, delayed recovery after general anesthesia is a common indication for ICU admi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years.
- • Scheduled to undergo elective surgery.
- • Planned ICU admission after surgery.
- Exclusion Criteria:
- • Refused to participate in the study.
- • ICU admission before surgery.
- • Unexpected ICU admission.
- • Other conditions that are considered unsuitable for study participation.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials